Grand Mal Seizure Market information: by drug generation (first, second, third), by drug class (barbiturates, hydantoin, others), by surgery (resective surgery, others), by diagnosis (EEG, MRI, others), and by end users - Global forecast till 2030

Table of contents

1. Introduction

1.1 Definition

1.2 scope of study

1.2.1 Research Objective

1.2.2 Assumptions & Limitations

1.2.2.1 Assumptions

1.2.2.2 Limitations

1.3 Market Structure

2. Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3. Market dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Macroeconomic Indicators

4. Market factor analysis

4.1 Porters Five Forces Model

4.2 Bargaining Power of Suppliers

4.3 Bargaining Power of Buyers

4.4 Threat of New Entrants

4.5 Threat of Substitutes

4.6 Intensity of Rivalry

5. Global Grand Mal Seizure Market, by Drug Generation

5.1 First Generation

5.2 Second Generation

5.3 Third Generation

6. Global Grand Mal Seizure Market, by Drug Class

6.1 Barbiturates

6.2 Hydantoin

6.3 Cyclic Gaba Analogues

6.4 Phenyltriazine

6.5 Iminostilbenes

6.6 Aliphatic Carboxylic Acid

6.8 Benzodiazepines

6.9 Others

7. Global Grand Mal Seizure Market, by Surgery

7.1 Resective Surgery

7.2 Multiple Subpial Transection

7.3 Hemispherectomy

7.4 Corpus Callosotomy

7.5 Others

7.7 Aliphatic Carboxylic Acid

8. Global Grand Mal Seizure Market, by Diagnosis

8.1 Electroencephalogram (EEG)

8.2 Magnetic Resonance Imaging (MRI)

8.3 Computed Tomography (CT)

8.4 Blood Tests

8.5 Others

9. Global U reteral Obstruction Market, by End Users

9.1 Hospitals

9.2 Neurological Centers

9.3 Academic and Research Centres

9.4 Others

10. Global Grand Mal Seizure Market, by Region

10.1 North America

10.1.1 Introduction

10.2 Europe

10.2.1 Introduction

10.3 Asia-Pacific

10.3.1 Introduction

10.4 Middle East & Africa

10.4.1 Introduction

11. Competitive landscape

11.1 Major Strategies Adopted by Market Players

11.1.1 Strategic Partnership

11.1.2 Merger & Acquisition

12. Company profile

12.1 Pfizer, Inc.

12.1.1 Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 Key Developments

12.2 Johnson & Johnson Services, Inc.

12.2.1 Overview

12.2.2 Product Overview

12.2.3 Financials

12.2.4 Key Developments

12.3 UCB Celltech

12.3.1 Overview

12.3.2 Product Overview

12.3.3 Financials

12.3.4 Key Development

12.4 Abbott Laboratories

12.4.1 Overview

12.4.2 Product Overview

12.4.3 Financials

12.4.4 Key Developments

12.5 GlaxoSmithKline plc

12.5.1 Overview

12.5.2 Product Overview

12.5.3 Financials

12.5.4 Key Developments

12.6 Novartis AG

12.6.1 Overview

12.6.2 Product Overview

12.6.3 Financials

12.6.4 Key Developments

12.7 Sanofi

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.8 Shire Pharmaceuticals Limited

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.9 Teva Pharmaceutical Industries

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Developments

12.10 Other

13. Conclusion

13.1 Key Findings

13.1.1 From CEO’s Viewpoint

13.1.2 Unmet Needs of The Market

13.2 Key Companies to Watch

13.3 Prediction of Grand Mal Seizure Industry

14. Appendix